Study Detail


A randomised, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.

Status: Open

Type: Interventional

Funder: GlaxoSmithKline

Sponsor: GlaxoSmithKline

CI: not available

IRAS-Number: 283089

CPMS-ID: 45580

Approval Date: 07 May 2020


The aim of this randomized, double-blind, placebo-controlled, study is to evaluate the benefit-risk of a single infusion of otilimab in the treatment of hospitalised participants with severe COVID-19 related pulmonary disease.

Back to listing